MedPath

Biphasic Material With PRF in Lateral Sinus Floor Augmentation

Phase 1
Not yet recruiting
Conditions
Maxillary Sinus Disease
Interventions
Procedure: Lateral sinus floor augmentation
Procedure: Injectable platlets rich fibrin
Registration Number
NCT06071416
Lead Sponsor
Assiut University
Brief Summary

A lack of bone in the posterior maxilla, mainly resulting from the combination of alveolar bone resorption after tooth loss, pneumatization of the maxillary sinus, and periodontal disease, leads to increased difficulty during dental implant treatment.

The classic technique for maxillary sinus floor augmentation entails the preparation of the trap door to elevate the schneiderian membrane in the lateral sinus wall. it can be done either in a single stage with simultaneous implant placement or in two stages with delayed implant placement, depending on the available residual alveolar ridge height that necessary for implant primary stability.

The new compartment created between the floor of maxillary sinus and the elevated membrane was filled with either autogenous, allografts, xenograft or combination of them to maintain space for new bone formation. The disadvantages of such methods are high costs for grafting material, time consuming and high morbidity, because harvesting of bone grafts is needed.

Detailed Description

Recently, a systematic review demonstrated the effectiveness of synthetic bone materials, including biphasic calcium phosphate (BCP), as substitutes for autogenous bone. BCP consists of hydroxyapatite (HA) and β-tricalcium phosphate (β-TCP). In contrast with stable HA, β-TCP is highly resorptive and is replaced by newly formed bone; therefore, the resorption rate of BCP could be influenced by the ratio of HA and β-TCP.

platelet-rich fibrin (PRF) was recently introduced as additional or replacement materials in bone augmentation procedures. The use of biologic mediators with osteoinductive properties has been considered to reduce the time interval and accelerate the formation of new bone. The strengths of PRF in reducing tissue inflammation, promoting the vascularization of bone tissue, accelerating new bone formation, and improving scaffold mechanics have been reported.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
18
Inclusion Criteria
  • Residual bone crest height < 5 mm and width≥6 mm in the planned implant site.
  • Healed bone crest (at least 6 months elapsed from tooth loss/extraction);
Exclusion Criteria
  • Absolute medical contraindications to implant surgery such as uncontrolled diabetes mellitus, blood platelet disorders, serious osseous disorders, and cardiac arrhythmia; history of bone grafting in the posterior maxilla, immunocompromised patients, taking corticosteroids, taking aspirin before the procedure, positive history of chemotherapy and radiotherapy, and maxillary sinus pathologies

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group 1 BCP aloneLateral sinus floor augmentationLateral bone augmentation with biphasic calcium phosphate BCP bone substitute application
Group 2 BCP with I-PRFLateral sinus floor augmentationLateral bone augmentation with biphasic calcium phosphate BCP bone substitute application with addition of injectable platlet rich fibrin I-PRF
Group 2 BCP with I-PRFBiphasic Calcium PhosphateLateral bone augmentation with biphasic calcium phosphate BCP bone substitute application with addition of injectable platlet rich fibrin I-PRF
Group 2 BCP with I-PRFInjectable platlets rich fibrinLateral bone augmentation with biphasic calcium phosphate BCP bone substitute application with addition of injectable platlet rich fibrin I-PRF
Group 1 BCP aloneBiphasic Calcium PhosphateLateral bone augmentation with biphasic calcium phosphate BCP bone substitute application
Primary Outcome Measures
NameTimeMethod
Vertical bone gain BG6 months

Vertical bone gain (BG) 6 months after sinus augmentation in both height and density aspects by cone beam CT

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath